Category: Markets
Published: 2026-06-22T16:09:23.000Z
Revvity is strategically expanding its Signals BioDesign software to enhance complex biologic research workflows, positioning itself in the life sciences sector alongside major players like Thermo Fisher and Danaher. The company's focus on software platforms aims to create recurring revenue and integrate customers more deeply into its broader portfolio, which includes reagents, imaging systems, and automation solutions. Revvity operates with two main segments, Life Sciences and Diagnostics, with its shares trading on the NYSE.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.